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Many anticancer drugs have an impaired bioavailability and poor brain penetration because they are sub-
strates to drug efﬂux pumps such as P-glycoprotein and Breast Cancer Resistance Protein. Elacridar is a strong
inhibitor of these two drug efﬂux pumps and therefore has great potential to improve oral absorption and
brain penetration of many anticancer drugs. Currently, a clinical formulation of elacridar is unavailable and
therefore the pharmaceutical development of a drug product is highly warranted. This also necessitates the
availability of an analytical method for its quality control. A reverse-phase high-performance liquid chro-
matographic method with ultraviolet detection was developed for the pharmaceutical quality control of
products containing elacridar as the active pharmaceutical ingredient. The analytical method was validated
for linearity, accuracy, precision, selectivity, carry-over, stability of stock and reference solutions, stability of
the ﬁnal extract, stability-indicating capability and impurity testing. We found that elacridar is unstable in
aqueous solutions that are exposed to light because a hydroxylation product of elacridar is formed. Therefore,
sample solutions with elacridar must be protected from light.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
One of the important reasons for chemotherapy failure is the
fact that many anticancer agents cannot reach tumor cells in suf-
ﬁcient quantities. This is often the result of drug-efﬂux pumps
Permeability Glycoprotein (PgP) and Breast Cancer Resistance
Protein (BCRP), which are present in the gastro-intestinal tract, at
the blood-brain barrier and in tumor cells [1–4]. A drug that is a
substrate for PgP and/or BCRP cannot enter the cell and therefore
cannot be absorbed into the central systemic circulation, brain and
tumor. Examples of anticancer drugs that are substrates of PgP/
BCRP are topotecan, paclitaxel, docetaxel, erlotinib, pazopanib,
imatinib and nilotinib [5,6].
Elacridar or N-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2
(1 h)-yl)ethyl)phenyl)5-methoxy-9-oxo-9,10-dihydroacridine-4-
carboxamide (GF120918) is an inhibitor of PgP and BCRP [7] and,
as conﬁrmed in several clinical trials, it can increase the oral
bioavailability of orally administered anticancer drugs such ason and hosting by Elsevier B.V. Th
University.
icki).paclitaxel and topotecan [8–12]. Furthermore, in pre-clinical re-
search elacridar inhibited PgP at the blood-brain barrier and
consequently increased the penetration of various anticancer
agents in the brain [13–21]. More clinical trials are warranted to
study the boosting effect of elacridar but cannot be performed
because currently there is no clinical formulation available.
Therefore, we developed a tablet formulation containing 23.5 mg
of elacridar as the active pharmaceutical ingredient (API). The
formulation is to be used in proof-of-concept clinical studies that
study the boosting effect of elacridar on various anticancer agents.
An amorphous solid dispersion was made to improve the poor
solubility in water [12]. In an amorphous solid dispersion the drug
is molecularly dispersed into a hydrophilic amorphous polymer
[22] and the presence of a hydrophilic polymer and amorphous
drug particles result in improved drug solubility [23]. This new
formulation also necessitated the availability of a validated ana-
lytical method for its quality control. There are currently no quality
control monographs about elacridar published in the European
Pharmacopoeia, United States Pharmacopoeia or Japanese Phar-
macopoeia nor are there validated analytical methods for
pharmaceutical quality control published in scientiﬁc literature. In
this paper we describe the development and validation of a re-
verse-phase high-performance liquid chromatography–ultravioletis is an open access article under the CC BY-NC-ND license
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trol of a drug powder, an amorphous solid dispersion and a tablet
formulation containing elacridar as the API.Fig. 1. Synthesis of elacridar hydrochloride according to the procedure as described
in reference [25]. 5-MODICA ¼5-Methoxy-9-oxo-9,10-dihydroacridine-4-carboxylic
acid, 4-DTHIA ¼4-[2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolinyl)ethyl]aniline.
TBTU ¼2-(1H-benzotriazole-1-yl)1,1,3,3-tetramethyluronium tetraﬂuoroborate,
DMF ¼ N,N-dimethyl formamide, IPA ¼ isopropanol, H2O¼water, EtOH ¼ ethanol,
HCl ¼ hydrochloric acid.2. Materials and methods
2.1. Chemicals
5-Methoxy-9-oxo-9,10-dihydroacridine-4-carboxylic acid (5-
MODICA) and 4-[2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolinyl)
ethyl]aniline (4-DTHIA) were purchased from AvaChem Scientiﬁc
(San Antonio, TX, USA). Dimethyl sulphoxide (DMSO), acetonitrile,
potassium dihydrogen phosphate and sodium dodecyl sulphate
(SDS) were purchased from Merck (Darmstadt, Germany). The
preparation of Simulated Intestinal Fluid without pancreatic en-
zymes (SIFsp, pH 6.8) was according to [24]. Distilled water was
from B. Braun (Melsungen, Germany). Povidone K30 was from BasF
Chemtrade (Ludwigshafen, Germany). Granulated lactose mono-
hydrate SuperTab
s
30GR was from DFE Pharma (Goch, Germany).
Colloidal silicon dioxide and magnesium stearate were from Fagron
(Capelle a/d Ijssel, The Netherlands). Croscarmellose sodium was
from FMC (Philadelphia, USA).
2.2. Drug powder and formulated products
The drug powder was elacridar hydrochloride (purity 499%)
and was synthesized according to the procedure as described in
[25]. A summary of this synthesis is displayed in Fig. 1.
The entire production process was compliant with Good
Manufacturing Practices. The intermediate product was an amor-
phous solid dispersion. For this, a solution of elacridar hydro-
chloride-povidone K30-SDS (12.5:75:12.5, m/m/m) in DMSO was
prepared to a total excipient concentration of 80 mg/mL. The solu-
tion was transferred to stainless steel boxes (Gastronorm 1/9, The
Netherlands). DMSO was removed by lyophilization and this was
performed according to a process earlier used by den Brok et al. [26]
in a Lyovac GT4 (GEA Lyophil, Hürth, Germany). The intermediate
product was a yellow powder stored in a glass bottle with an air-
tight polypropylene screw cap in the dark at 2 – 8 °C in a desiccator.
The ﬁnal drug product was a tablet with 23.5 mg elacridar
(corresponding to 25 mg elacridar hydrochloride). For this, a
powder mixture of intermediate product-granulated lactose
monohydrate-croscarmellose sodium-anhydrous colloidal silicon
dioxide-magnesium stearate (30:63:5:1:1, m/m/m/m/m) was
weighed in a 2 L stainless steel box and mixed in a Turbula Mixer
T10B (Willy A. Bachofen, Muttenz, Switzerland) for 30 min. The
powder mixture was then pressed on an eccentric tablet press
(Korsch, EK0, Berlin, Germany) and tablets were sealed in alumi-
num blisters and stored at – 20 °C in the dark until analysis.
2.3. Sample preparation
Stock solutions contained 188 mg/mL elacridar (200 mg/mL ela-
cridar hydrochloride) in DMSO and were stored in polypropylene
tubes in the dark at – 20 °C.
Calibration standards (CAL, 1–20 mg/mL elacridar hydro-
chloride) were prepared on the day of analysis from a stock so-
lution and diluted to the desired concentration in SIFsp-DMSO
(33:67, v/v). Quality control standards (QC, 1–20 mg/mL elacridar
hydrochloride) were diluted to the desired concentration in SIFsp-
DMSO (33:67, v/v) from a separately prepared stock solution.
For the preparation of reference solutions (10 mg/mL elacridar
hydrochloride), two separately prepared stock solutions were di-
luted in water-DMSO (20:80, v/v). Reference solutions were freshly
prepared for every analytical batch.For the quality control of drug powder and intermediate product,
an amount equivalent to 23.5 mg elacridar (25 mg elacridar hydro-
chloride) was dissolved in 50 mL DMSO by using a shaker. 0.200 mL
of this solution was added to 7.800 mL of DMSO in a polypropylene
tube. A volume of 2.000 mL water was added and homogenized.
For the quality control of the ﬁnal drug product, tablets in blister
package (stored at – 20 °C) were placed in the dark for 1.5 h in a
desiccator to prevent the adsorption of water when the tablets
reach ambient temperature. Subsequently, the tablet was pulverized
with a mortar and pestle and dissolved in 50 mL DMSO. The
Table 1
Validation of the HPLC–UV method (concentrations expressed as elacridar hydrochloride).
Validation
parameter
Conditions Matrix n Nominal concentration
(mg/mL)
Measured concentration
(mg/mL)
Pre-deﬁned criteria Result
Linearity Inter-run SIFsp-DMSO
(33:67, v/v)
36 1.00–20.09 1.01–20.27 RZ0.995 R: 1.000
6 1.00 1.01 Dev r74% 1.00%
6 3.35 3.35 Dev r74% 0.00%
6 8.37 8.24 Dev r73% 1.55%
6 13.39 13.27 Dev r73% 0.90%
6 16.74 16.78 Dev r73% 0.24%
6 20.09 20.27 Dev r73% 0.90%
Accuracy Inter-run SIFsp-DMSO
(33:67, v/v)
10 1.00 1.00 Bias r74% 0.00%
10 3.33 3.38 Bias r74% 1.50%
10 8.33 8.27 Bias r73% 0.72%
10 16.66 16.60 Bias r73% 0.36%
10 19.99 20.25 Bias r73% 1.30%
Precision Inter-run SIFsp-DMSO
(33:67, v/v)
10 1.00 1.00 RSD r74% 1.45%
10 3.33 3.38 RSD r74% 1.94%
10 8.33 8.27 RSD r73% 0.26%
10 16.66 16.60 RSD r73% 0.28%
10 19.99 20.25 RSD r73% 0.51%
Selectivity Blank tablet* Water-DMSO
(20:80, v/v)
3 – – No peaks at tr elacridar No peak
detected
Carry-over CAL 16.74 mg/mL, then fol-
lowed by matrix solution
SIFsp-DMSO
(33:67, V/V)
4 – – r20% of the lower limit
of quantiﬁcation
No peak de-
tected
Stability of stock
solution
20 °C, dark DMSO
11 months 5 201.78 199.58 Bias r73% 1.09%
21 months 5 200.40 197.66 Bias r73% 1.37%
15–25 °C, indoor natural
daylight, 24 h
DMSO 5 201.78 203.84 Bias r73% 1.02%
Stability of reference
solution
4 days, 2–8 °C, dark Water-DMSO
(20:80, v/v)
5 10.09 10.11 Bias r73% 0.20%
Stability of ﬁnal
extract
7 days, 2–8 °C, dark SIFsp-DMSO
(33:67, v/v)
2 1.00 1.03 Bias r74% 3.00%
2 3.35 3.41 Bias r74% 1.79%
2 8.37 8.25 Bias r73% 1.43%
2 13.39 13.12 Bias r73% 2.02%
2 16.74 16.83 Bias r73% 0.54%
2 20.09 20.65 Bias r73% 2.79%
RSD¼relative standard deviation, Dev¼deviation from linear ﬁt.
* Blank tablet contains the same ingredients and in the same proportions as in an elacridar solid dispersion tablet except elacridar hydrochloride.
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the supernatant was added to 7.800 mL of DMSO. Then 2.000 mL of
water was added to the polypropylene tube and the solution was
homogenized.
Aqueous samples were protected from light by transferring
them to amber-colored autosampler vials immediately after pre-
paration and by storing vials at 2 – 8 °C until and during analysis.
Samples were analyzed directly after preparation.
2.4. Instruments
The HPLC–UV system consisted of an 1100 Series binary HPLC
pump Model G1312A, 1100 series G1367A autosampler and 1100
series G1314A UV detector (Agilent Technologies, Santa Clara, CA,
USA). The column was a Waters Symmetry end-capped C-18 de-
activated silica column (150 mm4.6 mm, 3.5 mm). The eluent
was an isocratic mixture of ammonium acetate (pH 5.0, 120 mM):
acetonitrile (52.5:47.5, v/v) at a ﬂow of 0.5 mL/min and ambientcolumn temperature. Quantiﬁcation was executed at 259 nm. The
runtime was 10 min, sample injection volume was 10 mL and the
autosampler temperature was 571 °C.
2.5. Method validation
Validation of the HPLC–UV method was based on the procedure
as published by the ICH guideline on validation of analytical pro-
cedures [27]. Pre-deﬁned acceptance criteria are shown in Table 1.
2.5.1. Linearity
CALs were prepared according to Section 2.3, and analyzed in
duplicate and in three different analytical batches. Least-squares
linear regression was applied on the concentration versus peak
area plot and the correlation coefﬁcient (R) was calculated. De-
viations from linear ﬁt were established by comparing the back-
calculated concentrations with the nominal concentrations of the
calibration standards.
Fig. 2. (A) HPLC–UV chromatogram of a reference solution (10 mg/mL elacridar
hydrochloride in water-DMSO (20:80, v/v) that was stored for 24 h either in the
dark or in indoor natural daylight and UV–vis absorption spectra of (B) elacridar
and (C) the degradation product.
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QC samples were analyzed in ﬁve-fold and on two different
occasions. For each batch freshly prepared QCs and CALs were
used. Concentrations in the QC samples were calculated by least-
squares linear regression. The bias was calculated by dividing the
difference between the measured concentration and the nominal
concentration by the nominal concentration. Intra-run accuracy
was obtained by calculating the average bias of ﬁve analyzed QCs
per analytical batch per concentration level. Inter-run accuracy
was obtained by calculating the average bias of all analyzed QCs on
the two different analysis occasions per concentration level.
2.5.3. Precision
QC samples that were used to assess the accuracy were also
used to determine the intra-run precision (repeatability [27]) and
inter-run precision (intermediate precision [27]). For intra-runprecision the relative standard deviation (RSD) of the measured
concentration of each QC per analytical batch per concentration
level was calculated. For inter-run precision the RSD of the mea-
sured concentration of QCs of the two different analytical batches
per concentration level was calculated.
2.5.4. Selectivity
Three “blank tablets” which contained all ingredients of the
ﬁnal drug product except the drug powder were used. Each blank
tablet was processed as described in Section 2.3 and analyzed
immediately after preparation.
2.5.5. Carry-over
After analysis of the upper limit of quantiﬁcation (calibration
standard containing 16.7 mg/mL) blank matrix samples (SIFsp:
DMSO (33:67, v/v) were analyzed. The procedure was repeated
twice and performed on two different analysis days.
2.5.6. Stability of stock and reference solutions
Stock solutions were analyzed after 11 months and 21 months
of storage at – 20 °C and after 24 h at room temperature in indoor
natural daylight. Stock solutions were prepared according to
Section 2.3 and analyzed in ﬁve-fold. The concentration was
measured using a reference solution prepared from a fresh stock
solution. Reference solutions were stored for 4 days in the dark at
2–8 °C and quantiﬁed using freshly prepared reference solutions.
The bias was calculated by the same formula as described in
Section 2.5.2.
2.5.7. Stability of the ﬁnal extract
Calibration standards were analyzed at t¼0 and after 7 days of
storage in the dark at 2–8 °C and quantiﬁed by least-squares linear
regression using freshly prepared CALs. The bias and RSD were
calculated by the same formula as described in Section 2.5.2.
2.5.8. Stability-indicating capability
Reference solutions were prepared according to Section 2.3 and
exposed to various stress factors: 1 M sodium hydroxide, 1 M hy-
drochloric acid or 25% hydrogen peroxide. Duplicate samples of
each type of stress factor were prepared and one sample was
stored in the dark and the other sample was stored for 24 h in
indoor natural daylight. Samples were processed and analyzed
immediately after preparation and after 24 h.
2.5.9. Impurity test
5-MODICA (10 mg/mL in water-DMSO (20:80, v/v)) and 4-DTHIA
(10 mg/mL in water-DMSO (20:80, v/v)) were used to assess the
ability of the analytical method to separate impurities related to
the drug powder. Samples were measured on an HPLC system
coupled to a photo diode array detector (Ultimate 3000 Series,
Thermo Scientiﬁc, Waltham, MA, USA). Eluent, column, ﬂow rate
and injection volume were equal to those described in Section 2.4.
Ultra-violet and visible light (UV–vis) spectra were recorded from
200 nm to 800 nm.
2.6. Application of the HPLC–UV method
The HPLC–UV method was used to assess the content, purity
and dissolution of the drug powder, intermediate product and ﬁ-
nal drug product. To determine content and purity samples were
prepared according to Section 2.3 and were quantiﬁed using re-
ference solutions.
Dissolution was tested in a European Pharmacopoeia dissolu-
tion tester (Erweka, Heusenstamm, Germany) with a type II paddle
at 100 rpm [28]. SIFsp (pH 6.8, 37 °C) [24] was the dissolution
medium. The ﬁnal drug product was placed in a vessel with
Fig. 3. The peak area of degradation product (retention time: 6 min) when 10 mg/mL elacridar hydrochloride in water-DMSO (20:80, v/v) reference solution is exposed to
water, 1 M hydrochloric acid, 25% hydrogen peroxide or 1 M sodium hydroxide and stored for 24 h at room temperature (A) in the dark or (B) in indoor natural daylight.
Fig. 4. HPLC–UV chromatograms showing that (A) a solution of 10 mg/mL 5-Methoxy-9-oxo-9,10-dihydroacridine-4-carboxylic acid (5-MODICA) or (B) 10 mg/mL 4-[2-(3,4-
Dihydro-6,7-dimethoxy-2(1 h)-isoquinolinyl)ethyl]benzenamine (4-DTHIA) did not elute at the retention time of elacridar because they eluted at the dead-time (around
3 min).
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were taken at 0, 15, 30, 45, 60, 90, 120, 180 and 240 min. 1 mL of
each sample was directly ﬁltrated through a 0.45 mm PVDF ﬁlter
(Darmstadt, Germany) and diluted with 2 mL DMSO. CALs and QCs
were freshly prepared according to Section 2.3. Samples were
processed immediately after collection, protected from light by
transferring them to amber-colored autosampler vials and stored
at 2 – 8 °C until and during analysis.
2.7. Characterization of the degradation product
Two reference solutions were prepared according to Section
2.3. One reference solution was stored for 4 days in indoor natural
daylight at 15 – 25 °C and the other was stored for 4 days in the
dark at 15 – 25 °C. Samples were analyzed on an HPLC system
coupled to a LTQ XL Iontrap (Thermo Scientiﬁc, Waltham, MA,
USA) operating in the negative ionization mode. The eluent was
ammonium acetate (pH 5.0, 20 mM)-acetonitrile (65:35, v/v) and
the ﬂow was 0.5 mL/min. The column was a Waters Symmetry
C-18 (150 mm x 4.6 mm, 3.5 mm) at ambient temperature. Samples
were stored in a dark autosampler at 571 °C. 10 mL of sample
solution was injected and the run time was 45 min.3. Results and discussion
3.1. Liquid chromatography method development
The literature currently describes at least ﬁve HPLC methodsfor elacridar quantiﬁcation [18,29–32]. One of them used an
HPLC–UV method with isocratic eluent ammonium acetate
(pH 5.0, 200 mM)-acetonitrile-methanol (57.2:35:7.8, v/v/v) and a
retention time of 11 min [31]. The concentration of ammonium
acetate was lowered to 120 mM and acetonitrile was used as
modiﬁer to improve the peak shape. Using this eluent the reten-
tion time was around 7 min and the total run time was 10 min.
The original HPLC–UV method detected at 227 nm because in
this method a wavelength was required that could also detect two
other analytes (paclitaxel and docetaxel) [31]. For the develop-
ment of an HPLC–UV for elacridar quality control, the detection
wavelength was changed to 259 nm because the signal-to-noise
ratio of elacridar was approximately 34 times higher than at
227 nm.
3.2. Method validation
The results for linearity, accuracy, precision, selectivity, carry-
over, stock and reference solution stability and stability in the ﬁnal
extract are shown in Table 1. Linearity, inter-run accuracy and
inter-run precision complied with the criteria. Intra-run accuracy/
precision criteria were the same as inter-run accuracy/precision
and were also fulﬁlled. No other components of the ﬁnal drug
product eluted at the retention time of elacridar and there was no
carry-over. Stock solutions were stable at – 20 °C for at least 21
months and for 24 h at room temperature in light, reference so-
lutions could be stored at 2 – 8 °C in the dark for at least 4 days and
ﬁnal extracts were stable for at least 7 days at 2 – 8 °C in the dark.
The stability-indicating capability of the analytical method was
Fig. 5. Dissolution of the ﬁnal drug product (solid dispersion tablets, n¼6) and a
physical mixture of crystalline elacridar hydrochloride-PVPK30-SDS (1:6:1, m/m/m,
n¼3) in 500 mL SIFsp in the European Pharmacopoeia type II paddle dissolution
tester and quantiﬁcation with the validated HPLC–UV method.
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xide, hydrogen peroxide or hydrochloric acid. Fig. 2A shows a
chromatogram of a reference solution that was stored for 24 h in
the dark or in indoor natural daylight. In reference solutions that
were stored in the light two peaks were detected after the dead-
time: one peak corresponded to elacridar and the other peak
eluted approximately after 6 min. The sum of the peak areas at
6 min and elacridar peak area equaled the area of an elacridar
peak from a freshly prepared reference solution (Fig. 2A).
According to Fig. 3 the degradation product developed pre-
dominantly in neutral solutions and in solutions exposed to so-
dium hydroxide and was less prominent in solutions that were
exposed to hydrogen peroxide or hydrochloric acid. This suggested
that the unknown peak was a light-induced degradation product
of elacridar. The UV–vis absorption spectra of elacridar and the
degradation product are shown in Figs. 2B and Fig. 2C, respec-
tively. The degradation product contained an extra absorption
maximum at 312 nm, indicating that the chromophore of elacridar
was altered. The degradation product was also detected in for-
mulation sample solutions with water-DMSO and SIFsp-DMSO
that were stored for 24 h in the light.
For the impurity test two elacridar-related impurities
(5-MODICA and 4-DTHIA) were analyzed and their chromato-
grams are shown in Fig. 4A and Fig. 4B, respectively. 5-MODICA
and 4-DTHIA did not elute at the retention time of elacridar and
therefore the analytical method passed the impurity test.Fig. 6. HPLC–MS chromatograms of a reference solution stored at room temperature for
m/z 562 (elacridar) and m/z 578 (degradation product).3.3. Application of the HPLC–UV method
The HPLC–UV method was successfully validated in order to
analyze the purity, content and dissolution of the drug powder,
intermediate product and ﬁnal drug product. As an example, the
content in a batch ﬁnal drug product was 99.5%72.0% and the
purity was 100.0%70.0% after one week of storage at – 20 °C.
An example of the dissolution proﬁle of the ﬁnal drug product
and a crystalline physical mixture (elacridar hydrochloride-
PVPK30-SDS (1:6:1, m/m/m) are shown in Fig. 5. The low dis-
solution in crystalline physical mixture was caused by the low
solubility of crystalline elacridar in water as previously reported
[18]. The solid dispersion tablet signiﬁcantly increased the dis-
solution of elacridar; however, after 60 min the concentration
decreased due to recrystallization.
3.4. Characterization of the unknown degradation product
To characterize the degradation product, MS and MS2 spectra
were obtained. The eluent of the validated HPLC–UV method was
not MS-compliant because it contained an ammonium acetate
concentration that induced ion suppression. Therefore, the am-
monium acetate concentration in the eluent was lowered to
20 mM. Additionally, the acetonitrile content in the eluent was
lowered to 35% to improve the separation between elacridar and
the degradation product. Fig. 6 shows the HPLC–MS chromato-
grams of a reference solution that was stored for 4 days in the dark
(Fig. 6A) or 4 days in indoor natural daylight (Fig. 6B). Elacridar
(parent ion m/z 562) eluted at 31 min and was detected in both
samples; however, the peak height was decreased in the solution
that was stored in indoor natural daylight. The degradation pro-
duct (parent ion m/z 578) eluted at 27 min and was only detected
in the reference solution that was stored in indoor natural day-
light. The 16 amu mass increase in the degradation product sug-
gested hydroxylation of elacridar. The MS and MS2 spectra of
elacridar are shown in Fig. 7A and they conﬁrmed the identity of
elacridar. The MS and MS2 spectra of the degradation product are
shown in Fig. 7B. Only product ions in the 5-methoxy-9-oxo-9,10-
dihydroacridine-4-carboxyl-ethylbenzenamine moiety were de-
tected and in this part of the molecule no fragments with an in-
crease of 16 amu were found. This indicates that the hydroxyl
group was probably bound to the dimethoxyisoquinyl moiety of
the molecule.
In the HPLC–MS chromatogram of the solution that was stored
in light, an ion of mass m/z 562 was detected at 27 min (Fig. 6B)
and at 31 min (elacridar). Although the mass of this ion was equal
to that of the parent ion of elacridar this ion was not associated4 days (A) in the dark or (B) in indoor natural daylight. Two traces were monitored:
Fig. 7. (A) MS (subgraph) and MS2 spectra of elacridar (parent ion m/z 562) from a reference solution (10 mg/mL elacridar hydrochloride water-DMSO (20:80, v/v) stored for
4 days in the dark at 15–25 °C (retention time 31 min) and (B) MS (subgraph) and MS2 spectra of the degradation product (parent ion m/z 578) from a reference solution
(10 mg/mL elacridar hydrochloride water-DMSO (20:80, v/v) that was exposed for 4 days to indoor natural daylight at room temperature (retention time 27 min). X, Y and Z
indicate the location of –CH3 groups in the molecule.
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in-source fragmentation of m/z 578 (loss of water) explains the
chromatographic peak detected at m/z 562 at the retention time of
the degradation product. This effect could not be avoided by
changing in-source ionization settings or by switching to positive
ionization mode. The loss of a water molecule due to in-source
fragmentation is common and was previously reported by us for
ecteinascidin-743 which was a compound where a hydroxyl group
coupled to a carbon atom next to an aliphatic amine group was
lost in electrospray mode [33]. A similar structure is present in the
degradation product.
To conclude, the fact that the degradation product elutes before
elacridar, that it is 16 amu heavier than elacridar and that it only
occurs in samples that are stored in indoor natural daylight con-
ﬁrms that it is caused by light-induced hydroxylation of elacridar.
The proposed structure of the degradation product is hydroxylated
elacridar and its chemical structure is presented in Fig. 7B.
4. Conclusion
An HPLC–UV method was developed and validated for the
pharmaceutical quality control of a drug powder, an amorphoussolid dispersion and a tablet formulation with elacridar as the API.
The HPLC–UV method can be used to analyze the content, purity
and dissolution. Light induces elacridar hydroxylation in aqueous
samples and therefore light protection is required.References
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